Loss of LYN is frequent in targeted-therapy resistant melanoma cells and favors metastatic properties.

tolimidone (MTX228) - Bukwang Pharma, Biodexa Pharma

http://www.ncbi.nlm.nih.gov/pubmed/39033988

Alexandra Picard-Gauci; Céline Gaudel; Céline Pisibon; Corine Bertolotto; Frédéric Soysouvanh; Justine Leclerc; Paul Hofman; Philippe Bahadoran; Robert Ballotti; Serena Giuliano

Jul 22, 2024